

04/04/01

JCS39 U.S. P.O.

UTILITY PATENT
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: NV1932

Page 1 of 2

Title IMPROVED METHOD FOR THE PRODUCTION
OF BACTERIAL TOXINS

Express Mail Label No.: EL524824495US

A
BoxSEAJ1044 U.S. PTO
09/825769

04/04/01

APPLICATION ELEMENTS

ADDRESS TO: Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231INVENTORS: Milan S. Blake
John A. Bogdan, Jr.
Javier Nazario-Larrieu

1. ☒ Fee Transmittal Form (Submit an original, and a duplicate for fee processing)
2. ☒ Specification [Total Pages
3. ☒ Drawing(s) (35 USC §113) [Total Pages (Figs. 1-9)
4. ☐ Signed Declaration [Total Pages

a. ☐ Newly executed (original or copy)

b. ☐ Copy from a prior application (37 CFR §1.63(d))

i. ☐ (Note Box 5 below)
DELETION OF INVENTOR(S)
Signed statement attached deleting inventor named in the prior application, see 37 CFR §§1.63(d)(2) and 1.33(b)

5. ☐ Incorporation By Reference (useable if Box 4b is checked.) T
entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein

6. ☒ Nucleotide and/or Amino Acid Sequence Submission

a. ☒ Computer Readable Copy
b. ☒ Paper Copy (identical to computer copy)
c. ☒ Statement Verifying identify of above copies

7. ☐ Assignment Papers (cover sheet & document(s))

8. ☐ 37 CFR §3.73(b) Statement ☐ Power of Attorney

9. ☐ English Translation Document

10. ☐ Information Disclosure Statement (IDS)/PTO-1449 ☐ Copies of IDS Citations

11. ☐ Preliminary Amendment

12. ☒ Return Receipt Postcard (MPEP 503)

13. ☐ Small Entity Statement(s)

14. ☐ Certified Copy of Priority Documents (s)

15a. ☐ Cancel in the application original claims before calculating the filing fee

15b. ☐ Amend the specification by inserting before the first line the sentence: -This is a Continuation, Divisional, Continuation-in-part, of application filed / /

15c. ☐ I hereby verify that the attached papers are a true copy of the latest inventor-signed prior application, including a copy of the oath or declaration showing the original signature or an indication it was signed. I hereby verify that the papers are a true copy of the latest signed prior application number / / filed / / and further that all statements made herein of my own knowledge are true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

15d. ☐ Other

15e. ☐ Other

16. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.: /

UTILITY PATENT
APPLICATION TRANSMITTAL

(Under 37 C.F.R. §1.53(b))

Docket No.: NV1932

Page 2 of 2

Title IMPROVED METHOD FOR THE PRODUCTION
OF BACTERIAL TOXINS


Express Mail Label No.: EL524824495US

CLAIMS	(1) FOR	(2) NUMBER	(3) NUMBER EXTRA	(4) RATE	(5) CALCULATIONS
	TOTAL CLAIMS (37 CFR 1.16(b))	8-20 =	0	X \$ <u>18</u> =	\$0
	INDEPENDENT CLAIMS (37 CFR 1.16(b))	3	0	\$ <u>80</u> =	\$0
	MULTIPLE DEPENDENT CLAIMS (if applicable) (37 CFR §1.16(d))			+ \$ <u>270</u> =	\$ 0
				BASIC FEE (37 CFR §1.16(a))	\$710.00
				TOTAL =	\$710.00

The Commissioner is hereby authorized to credit overpayments or charge the following fees, and any other fees necessary during the pendency of the application, to **Deposit Account No. 02 -1437 (Docket NV1932)**.
(For this purpose, pursuant to 37 CFR §1.136(a)(3) please incorporate the above authorization into any future reply as a petition for an appropriate extension of time if a petition for an extension of time is not otherwise provided.)

- a. ☒ Fees required under 37 CFR §1.16
- b. ☒ Fees required under 37 CFR §1.17
- c. ☒ Fees required under 37 CFR §1.18

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

NAME	C. Joseph Faraci, Reg. No. 32,350
SIGNATURE	
DATE	April 4, 2001

CORRESPONDENCE ADDRESS

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, California 92614
Telephone: (949) 250-6827 Fax: (949) 474-6330

CERTIFICATE OF MAILING UNDER 37C.F.R. §1.10


I hereby certify that the above-identified document is being deposited with the United States Postal Service as Express Mail, Label No. EL524824495US in an envelope addressed to: Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231 on April 4, 2001.

By: 
Diane Branham

CERTIFICATE OF MAILING

Date: April 4, 2001
Express Mailing Label No.: EL524824495US

I hereby certify that on the dated listed above, this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service in accordance with 37 C.F.R. § 1.10 as "Express Mail Post Office to Addressee," with sufficient postage in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, DC 20231.


Diane Branham

PATENT

Applicant: Blake, et al.

Serial No.: Not Yet Assigned

Filed: April 4, 2001

Title: **IMPROVED METHOD FOR
THE PRODUCTION OF
BACTERIAL TOXINS**

Examiner: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Atty Docket No.: NV1932

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**Submission of "Sequence Listing" and Computer readable Copy for Biotechnology Invention
Containing Nucleotide and/or Amino Acid Sequence (37 CFR §§ 1.821 - 1.825)**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In compliance with 37 CFR §§ 1.821-1.825 Applicant encloses a paper copy of the Sequence listing for the nucleotide and amino acid sequences disclosed in the above-identified application. A copy of the Sequence Listing in computer readable form is also submitted herewith.

**Statement That Computer Readable Copy
of Sequence Listing is the Same as
the Paper Copy of the Sequence Listing**

I hereby state:

1. The computer readable form of the Sequence Listing submitted in this application is the same as the paper copy of the "Sequence Listing" to which it is indicated to relate.
2. No new matter has been added to the computer readable copy or the paper copy of this Sequence Listing.

Dated: April 4, 2001


G. Joseph Farnesi

Baxter Healthcare Corporation
P.O. Box 15210
Irvine, CA 92623-5210
Telephone: (949) 250-6827
Facsimile: (949) 474-6330